| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/06/2005 | US20050002924 Pharmaceutical composition containing sFcgammaR IIb or sFcgammaR III |
| 01/06/2005 | US20050002922 Side effect free treatment of neuropsychiatric, neurological and behavioral disorders; anxiety; easy to administer; kits |
| 01/06/2005 | US20050002918 Selective treatment of IL-13 expressing tumors |
| 01/06/2005 | US20050002916 Cytokine-expressing cellular vaccine combinations |
| 01/06/2005 | US20050002915 Enhancement of angiogenesis to grafts using cells engineered to produce growth factors |
| 01/06/2005 | US20050002909 Methods and compositions for treating intervertebral disc degeneration |
| 01/06/2005 | US20050002908 Method for producing a recombinant adeno-associated virus, suitable means therefor and use for producing a medicament |
| 01/06/2005 | US20050002906 Preferentially amplifying in tumors following cancer cell activation of specific gene regulatory region |
| 01/06/2005 | US20050002902 Increasing active half life; reducing dosage and side effects |
| 01/06/2005 | US20050002901 Compositions and methods for treating coronavirus infection and SARS |
| 01/06/2005 | US20050002900 Inhibiting estradiol production in human adipocytes using interferon gamma and/or tumor necrosis factor antagonist and/or interleukin-1 antagonist; reducing side effects |
| 01/06/2005 | US20050002899 Serum and mitogen free; inducing tumor cells to enter proliferative cycle phase |
| 01/06/2005 | US20050002897 Biological entities and the pharmaceutical or diagnostic use thereof |
| 01/06/2005 | US20050002896 Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 01/06/2005 | US20050002875 Peptide which binds to integrin |
| 01/06/2005 | US20050002867 Buccal, polar and non-polar sprays containing propofol |
| 01/06/2005 | CA2839032A1 Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof |
| 01/06/2005 | CA2530111A1 Glycogen synthase kinase-3 inhibitors |
| 01/06/2005 | CA2530063A1 Compositions of lipopeptide antibiotic derivatives and methods of use thereof |
| 01/06/2005 | CA2530024A1 Melanocortin receptor 4(mc4) agonists and their uses |
| 01/06/2005 | CA2529943A1 Peptides derived from the protein mmp-2, and the use thereof in antitumoral immunotherapy |
| 01/06/2005 | CA2529873A1 Methods and compositions for treating rheumatoid arthritis |
| 01/06/2005 | CA2529840A1 Therapeutic agent for soft tissue sarcoma |
| 01/06/2005 | CA2529660A1 Vegf traps and therapeutic uses thereof |
| 01/06/2005 | CA2529522A1 Methioninase treatment for p.carinii infection |
| 01/06/2005 | CA2529371A1 Cytotoxic depsipeptides |
| 01/06/2005 | CA2529103A1 Use of a recombinant vector encoding il-10 for treating neuropathic pain |
| 01/06/2005 | CA2529010A1 Use of a clostridial toxin to reduce appetite |
| 01/06/2005 | CA2528723A1 Methods and compositions for treating rheumatoid arthritis |
| 01/06/2005 | CA2528591A1 Glp-1 analog fusion proteins |
| 01/06/2005 | CA2528434A1 Combination therapy for b cell disorders |
| 01/06/2005 | CA2528353A1 Compositions and methods for treatment of rosacea |
| 01/06/2005 | CA2528343A1 Modulating the interaction between hgf beta chain and c-met |
| 01/06/2005 | CA2528281A1 Methods for identifying agents, which regulate cytokines |
| 01/06/2005 | CA2528155A1 Compositions and methods for modulating s-nitrosoglutathione reductase |
| 01/06/2005 | CA2528067A1 Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli |
| 01/06/2005 | CA2527957A1 Use of genes differentially expressed during aging of liver for treatment and diagnosis |
| 01/06/2005 | CA2527881A1 Uses of melanocortin-3 receptor (mc3r) agonist peptides |
| 01/06/2005 | CA2527052A1 Angiogenic agents from plant extracts, gallic acid, and derivatives |
| 01/06/2005 | CA2526971A1 Novel dermatological composition |
| 01/06/2005 | CA2526490A1 Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof |
| 01/06/2005 | CA2526023A1 T24 antigen for immunodiagnosis of taenia solium cysticercosis |
| 01/06/2005 | CA2525987A1 Methods of treating hyperproliferative cell disorders |
| 01/06/2005 | CA2525928A1 A method of treating degenerative disc disease |
| 01/06/2005 | CA2525788A1 Anti-adhesion composites and methods of use thereof |
| 01/06/2005 | CA2522048A1 Methods to mobilize progenitor/stem cells |
| 01/05/2005 | EP1493813A1 Flagellar genetic sequences of Brucella being of therapeutic and diagnostic use |
| 01/05/2005 | EP1493812A2 A truncated keratinocyte growth factor (KGF) having increased biological activity |
| 01/05/2005 | EP1493810A1 DNA-based aptamers for human cathepsin G |
| 01/05/2005 | EP1493744A1 Tropane analogs and methods for inhibition of monoamine transport |
| 01/05/2005 | EP1493446A1 Modified truncated complement system regulators |
| 01/05/2005 | EP1493445A1 Inhibition of stress-induced ligand-dependent EGFR activation |
| 01/05/2005 | EP1493034A2 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity |
| 01/05/2005 | EP1493033A2 Sc6 for diagnosis of hypoxia related conditions |
| 01/05/2005 | EP1493028A2 Phage displayed pdz domain ligands |
| 01/05/2005 | EP1492885A2 Schizophrenia associated genes |
| 01/05/2005 | EP1492883A2 Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2) |
| 01/05/2005 | EP1492879A1 Chimeric cannulae proteins, nucleic acids encoding them and methods for making and using them |
| 01/05/2005 | EP1492878A1 Process for the preparation of a desired erythropoietin glyco-isoform profile |
| 01/05/2005 | EP1492876A1 Cationic amphiphiles for intracellular delivery of therapeutic molecules, composition, process and use thereof |
| 01/05/2005 | EP1492873A2 Lipase genes and proteins |
| 01/05/2005 | EP1492871A2 Cancer associated protein kinases and their uses |
| 01/05/2005 | EP1492868A2 Method of modulating inflammatory response |
| 01/05/2005 | EP1492819A2 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine |
| 01/05/2005 | EP1492816A2 Modulators of the notch signalling pathway and uses thereof in medical treatment |
| 01/05/2005 | EP1492815A2 Cells transfected with a nucleotide sequence encoding glp-1 and secreting insulin in a glucose-dependent manner |
| 01/05/2005 | EP1492814A2 Novel peptides and the application thereof in therapy |
| 01/05/2005 | EP1492813A2 Ox40r binding agents |
| 01/05/2005 | EP1492812A2 Modulator of the notch signalling pathway and use thereof in medical treatment |
| 01/05/2005 | EP1492811A1 Muteins of the c5a anaphylatoxin, nucleic acid molecules encoding such muteins, and pharmaceutical uses of muteins of the c5a anaphylatoxin |
| 01/05/2005 | EP1492808A2 Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof |
| 01/05/2005 | EP1492807A2 Novel proteins and nucleic acids encoding same |
| 01/05/2005 | EP1492780A1 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors |
| 01/05/2005 | EP1492596A1 Depsipeptide for therapy of kidney cancer |
| 01/05/2005 | EP1492595A1 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| 01/05/2005 | EP1492563A2 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 01/05/2005 | EP1492561A1 Methods for treating mammary gland disorders |
| 01/05/2005 | EP1492560A2 Use of interleukin-19 to treat cervical cancer |
| 01/05/2005 | EP1492559A2 Truncated 24 kda basic fibroblast growth factor |
| 01/05/2005 | EP1492557A2 Xcrf polynucleotides and polypeptides and uses thereof |
| 01/05/2005 | EP1492556A1 Use of long pentraxin ptx3 for the treatment of fgf-8 mediated tumour diseases |
| 01/05/2005 | EP1492555A2 Compositions and methods for modulation of effects on phagocyte and lymphoid cell population |
| 01/05/2005 | EP1492554A2 Spherical protein particles and methods of making and using them |
| 01/05/2005 | EP1492553A2 Cg8327, cg10823, cg18418, cg15862, cg3768, cg11447 and cg16750 homologous proteins involved in the regulation of energy homeostasis |
| 01/05/2005 | EP1492552A2 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| 01/05/2005 | EP1492545A1 Agents for treating i flaviviridae /i infections |
| 01/05/2005 | EP1492525A2 Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
| 01/05/2005 | EP1492516A2 Use of mob-5 in pain |
| 01/05/2005 | EP1492504A2 Taste masked compositions of erythromycin a and derivatives thereof |
| 01/05/2005 | EP1492476A1 Device for mixing and/or injecting cements |
| 01/05/2005 | EP1492415A2 Method of improving absorption of vitamin e by a pet animal |
| 01/05/2005 | EP1492414A2 Method and dietary composition for improving fat digestibility |
| 01/05/2005 | EP1492413A2 Method and dietary composition for improving lipid digestibility |
| 01/05/2005 | EP1492409A2 Peptides with anti-hypertensive properties |
| 01/05/2005 | EP1397386A4 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same |
| 01/05/2005 | EP1301202A4 Genetically-engineered mhc molecules |
| 01/05/2005 | EP1227814B1 Hormonal composition based on nomegestrol acetate and an oestrogen and use thereof |
| 01/05/2005 | EP1152773B1 Methods of inactivating pathogens using broad-spectrum pulsed light |
| 01/05/2005 | EP1109537B1 Immediate release oral formulation comprising peptide thrombin inhibitors and a combination of microcrystalline cellulose and sodium starch glycollate |
| 01/05/2005 | EP1032371B1 Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances |